J. Goldman & Co LP Makes New $205,000 Investment in Cardiff Oncology, Inc. (NASDAQ:CRDF)

J. Goldman & Co LP acquired a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 47,250 shares of the company’s stock, valued at approximately $205,000. J. Goldman & Co LP owned approximately 0.09% of Cardiff Oncology as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CRDF. Bank of New York Mellon Corp lifted its holdings in Cardiff Oncology by 68.7% in the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company’s stock valued at $1,253,000 after purchasing an additional 117,514 shares in the last quarter. HB Wealth Management LLC acquired a new position in shares of Cardiff Oncology in the fourth quarter valued at approximately $105,000. American Century Companies Inc. lifted its stake in shares of Cardiff Oncology by 12.8% during the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company’s stock valued at $234,000 after buying an additional 6,140 shares during the period. Rhumbline Advisers boosted its position in Cardiff Oncology by 24.0% during the fourth quarter. Rhumbline Advisers now owns 53,172 shares of the company’s stock worth $231,000 after acquiring an additional 10,290 shares during the last quarter. Finally, Barclays PLC boosted its position in Cardiff Oncology by 291.9% during the third quarter. Barclays PLC now owns 53,089 shares of the company’s stock worth $141,000 after acquiring an additional 39,542 shares during the last quarter. 16.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright boosted their price target on Cardiff Oncology from $17.00 to $18.00 and gave the company a “buy” rating in a report on Friday.

Cardiff Oncology Price Performance

CRDF opened at $2.75 on Tuesday. Cardiff Oncology, Inc. has a 12 month low of $2.01 and a 12 month high of $5.64. The business has a 50-day moving average of $3.11 and a two-hundred day moving average of $3.47. The stock has a market capitalization of $182.95 million, a price-to-earnings ratio of -2.93 and a beta of 1.81.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.09 million. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. Equities research analysts anticipate that Cardiff Oncology, Inc. will post -0.99 earnings per share for the current year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.